Reports: Three states file suit against makers of 5-Hour Energy
NEW YORK — Three states are suing the makers of 5-Hour Energy for false claims, according to published reports. Oregon, Washington and Vermont have all filed suit and more states are expected to join in.
The state of Oregon maintains that the energy drink brand violated the Oregon Unlawful Trade Practices Act by making misleading claims about products, including false claims about special ingredients.
“This lawsuit is about requiring truth in advertising,” said Oregon Attorney General Ellen Rosenblum in a statement. “Plainly and simply, in Oregon you cannot promote a product as being effective if you don’t have sufficient evidence to back up your advertising claims.”
Washington and Vermont reflected similar views in their suits, according to reports. 5-Hour Energy is distributed by Living Essentials and is marketed as a liquid energy shot that is meant to keep consumers alert.
McKesson SVP public affairs announces retirement following storied career
ORLANDO, Fla. – McKesson's Frank Starn, SVP and COO of McKesson U.S. Pharmaceutical, announced that Ann Richardson Berkey, SVP public affairs for McKesson, will be retiring. "After an accomplished and storied 26-year career with McKesson, Ann has decided to retire from the company," Starn told attendees of McKesson's ideaShare here Wednesday morning. "Ann has been a very close colleague and dear friend for quite a long time. … I watched her build an incredibly strong public affairs group. She has vision; she has deep government relations and expertise," he said. "Over the years, Ann's leadership has successfully supported advanced public policies that have benefited McKesson, but also it's benefited our industry."
Berkey is responsible for corporate public policy strategy and communications, and for the management of federal, state and international government relations at McKesson. Prior to McKesson, Berkey was a principal at Berkey Associates, a government relations consulting firm in the Bay Area.
Earlier in her career, she managed state government relations for Shell Oil in the western region and federal government relations in their Houston headquarters. As a special assistant to two Cabinet officers (i.e., U.S. Departments of Health, Education and Welfare, and Interior) in the 1970s, she held responsibilities for special projects with governors, members of Congress and the White House, as well as political briefings.
Berkey has served on the Advisory Board of the Women Business Leaders of the U.S. Health Care Industry since 2001. She was chair of the board of directors of the Public Affairs Council in Washington and remains on their board. She joined the board of directors of the National Marrow Donor Program in 2011 as a patient family representative, following her husband's death from leukemia, and has served on their executive committee, compensation committee and board development committee. Berkey received a Bachelor of Arts degree from Mount Holyoke College.
She has two grown children and lives in Oakland, Calif.
Zydelig approved by FDA to treat three types of blood cancers
SILVER SPRING, Md. — The Food and Drug Administration on Wednesday announced approval for Zydelig (idelalisib) to treat patients with three types of blood cancers.
Traditional approval was granted to treat patients whose chronic lymphocytic leukemia has relapsed. The agency granted accelerated approval to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma, or FL, and relapsed small lymphocytic lymphoma, or SLL. The drug is intended to be used in patients who have received at least two prior systemic therapies, according to the agency.
“In less than a year, we have seen considerable progress in the availability of treatments for chronic lymphocytic leukemia,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Zydelig’s approval to treat CLL reflects the promise of the breakthrough therapy designation program and represents the FDA’s commitment to working cooperatively with companies to expedite a drug’s development, review and approval.”
Zydelig is designated as an orphan product because it is intended to treat a rare disease.